Elektrofi announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products. Elektrofi’s platform technology is designed to overcome the challenges of delivering biologic-based therapies by enabling patients to self-inject therapies at home rather than in a hospital setting. Based on strong preclinical validation and partner interest, the company expects to initiate multiple clinical trials in 2024. The collaboration with Thermo Fisher will facilitate the establishment of a platform cGMP line, scheduled to be operational in early 2024, that will support early clinical efforts across a wide variety of pipeline programs and enable rapid scale-up for late-stage and commercial development.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TMO:
- Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
- Thermo Fisher price target raised to $670 from $613 at Morgan Stanley
- Thermo Fisher price target raised to $711 from $690 at Cowen
- Thermo Fisher price target lowered to $693 from $710 at Baird
- Thermo Fisher price target raised to $660 from $630 at Barclays
